Clinical TrialAug 10, 2026, 08:03 AM
Silence Therapeutics divesiran Phase 2 PV trial positive; 88% response
AI Summary
Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial of divesiran for polycythemia vera (PV). The trial met its primary endpoint, showing a significantly higher proportion of clinical responders (88%) in the divesiran group compared to placebo (19%). Both Q6W and Q12W dosing regimens demonstrated substantial efficacy and the drug was well tolerated with no new safety concerns. The company plans to initiate a Phase 3 trial in the first half of 2027.
Key Highlights
- Phase 2 SANRECO trial of divesiran in PV met its primary endpoint.
- 88% of divesiran-treated patients were clinical responders vs. 19% for placebo (p<0.0001).
- Divesiran Q6W showed 93.8% response rate; Q12W showed 81.3% response rate.
- Mean phlebotomies reduced to 0.2 for divesiran vs. 2.1 for placebo (p<0.0001).
- Divesiran was well tolerated with no new safety findings.
- Company expects to initiate a Phase 3 trial in 1H 2027.
Price Impact
More from SLN